← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
The Univeristy Of Texas M.D. Anderson Cancer Center
$260,538,168
Total funding
309
Grants
Funding over time
peak $63.6M · FY2008–25$100M$75M$50M$25M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$258,072,019 · 304
NASA$1,562,888 · 3
USDA$909,615 · 1
DOE$-6,353 · 1
By mechanism
—$260,538,168 · 309
Investigators at The Univeristy Of Texas M.D. Anderson Cancer Center
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
CONVERGENT SCIENCE CANCER CONSORTIUM FOR IMMUNE CELL ENGINEERING$19,100,256
· FY2025 · Defense Health Agency
IMPACT: IMAGING & MOLECULAR MARKERS FOR PATIENTS WITH LUNG CANCER: APPROACHES W/ MOLECULAR TARGETS, COMP/INNOVATIVE TREAT., THERAPEUTI MODALITIES$8,653,000
· FY2008 · Department of Defense
CLINICAL CONSORTIUM AWARD - COORDINATING CENTER AND CLINICAL RESEARCH SITE$7,419,425
· FY2024 · Defense Health Agency
ADVANCING UNDERSTANDING OF METASTATIC BREAST CANCER THROUGH DEVELOPMENT OF A COMPREHENSIVE RESEARCH PLATFORM$7,001,734
· FY2024 · Defense Health Agency
KIDNEY CANCER CLINICAL TRIALS CONSORTIUM$5,898,796
· FY2020 · Defense Health Agency
TARGETING GANGLIOSIDE GD2 TO OVERCOME CHEMOTHERAPY RESISTANCE IN TRIPLE-NEGATIVE BREAST CANCER$5,471,258
· FY2025 · Defense Health Agency
CD79B-TARGETING CAR T-CELL THERAPY FOR B-CELL LYMPHOMAS$4,275,962
· FY2024 · Defense Health Agency
A MULTI-INSTITUTIONAL PROSPECTIVE OBSERVATIONAL STUDY ON NERVE REPAIR AND RECONSTRUCTION ASSOCIATED WITH MAJOR EXTREMITY TRAUMA$4,046,531
· FY2015 · Department of the Army
COMBATING TOBACCO USE IN THE UNITED STATES ARMY$3,777,742
· FY2009 · Department of Defense
GENOMIC INSTABILITY AND BREAST CANCER$3,725,000
· FY2008 · Department of the Army
CHARACTERIZING AND TARGETING REPLICATION STRESS RESPONSE DEFECTS IN BREAST CANCER$3,507,674
· FY2010 · Department of Defense
PHASE 1B/2 STUDY OF 177LU GIRENTUXIMAB PLUS CABOZANTINIB AND NIVOLUMAB IN TREATMENT-NAIVE PATIENTS WITH ADVANCED CLEAR CELL RCC$3,239,994
· FY2022 · Defense Health Agency
SYSTEMATIC INVESTIGATION OF KEY SURVIVAL AND GROWTH PATHWAYS IN BREAST CANCER$3,080,000
· FY2009 · Department of Defense
TARGETING LOCAL B CELLS TO PREVENT CHRONIFICATION OF NEUROPATHIC PAIN$3,064,079
· FY2025 · Defense Health Agency
ADVANCING UNDERSTANDING OF METASTATIC BREAST CANCER THROUGH DEVELOPMENT OF A COMPREHENSIVE RESEARCH PLATFORM$2,710,479
· FY2024 · Defense Health Agency
CHEMOIMMUNOTHERAPY FOR AGGRESSIVE VARIANT PROSTATE CANCERS (AVPC)$2,498,000
· FY2020 · Defense Health Agency
DETOXIFICATION OF ENVIRONMENTAL METALS TO IMPROVE OUTCOMES IN AML$2,429,999
· FY2024 · Defense Health Agency
EPIGENETIC MECHANISM AND TARGETING DURING RESPONSE TO BRAFI/ANTI-EGFR THERAPY IN BRAF-MUTANT COLORECTAL CANCERS$2,351,546
· FY2024 · Defense Health Agency
MODULATE INNATE IMMUNE RESPONSES TO CUSTOMIZE THERAPY IN ARID1A-DEFICIENT GASTRIC ADENOCARCINOMA$2,021,389
· FY2022 · Department of the Army
COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF HIGH RISK HER2 POSITIVE BREAST CANCER$1,987,155
· FY2014 · Department of the Army